Designing inhibitors of anthrax toxin

Ekaterina M Nestorovich† & Sergey M Bezrukov
†The Catholic University of America, Department of Biology, Washington, DC, USA

Introduction: Present-day rational drug design approaches are based on exploiting unique features of the target biomolecules, small- or macromolecule drug candidates and physical forces that govern their interactions. The 2013 Nobel Prize in chemistry awarded ‘for the development of multiscale models for complex chemical systems’ once again demonstrated the importance of the tailored drug discovery that reduces the role of the trial-and-error approach to a minimum. The intentional dissemination of Bacillus anthracis spores in 2001 via the so-called anthrax letters has led to increased efforts, politically and scientifically, to develop medical countermeasures that will protect people from the threat of anthrax bioterrorism.

Areas covered: This article provides an overview of the recent rational drug design approaches for discovering inhibitors of anthrax toxin. The review also directs the readers to the vast literature on the recognized advances and future possibilities in the field.

Expert opinion: Existing options to combat anthrax toxin lethality are limited. With the only anthrax toxin inhibiting therapy (protective antigen-targeting with a monoclonal antibody, raxibacumab) approved to treat inhalational anthrax, the situation, in our view, is still insecure. Further, the FDA’s animal rule for drug approval, which clears compounds without validated efficacy studies on humans, creates a high level of uncertainty, especially when a well-characterized animal model does not exist. Better identification and validation of anthrax toxin therapeutic targets at the molecular level as well as elucidation of the parameters determining the corresponding therapeutic windows are still necessary for more effective therapeutic options.

Keywords: antitoxins, Bacillus anthracis, binary toxins, polyvalent interactions, rational drug design


1. Introduction

Drug discovery strategies continuously evolve. Historically, drugs were discovered by serendipitous empirical approaches, by optimizing biologically active molecules provided by nature or by high-throughput screening of diverse chemical libraries [1]. In our days, because of the rapidly growing knowledge of the biological origins of many diseases, we are witnessing the emergence of novel rational drug discovery methods, where biologically active compounds are specifically designed and tuned to attack the exact disease targets [2]. These methods are based on exploiting unique features of the target biomolecules, small- or macromolecule drug candidates, and physical forces that govern their interactions. Rational drug design approaches often use computer-aided drug discovery methods where the 3D models of druggable targets and drug-like molecules are made [3]. However, the ‘rational drug design’ term is broader and could include all contemporary medicinal chemistry methods where serendipity and screening are substituted by the innovative and information-guided compound design.
2. Mode of action of anthrax toxin

*B. anthracis*, the causative agent of anthrax, is a large Gram-positive, rod-shaped, aerobic, spore-forming bacterial pathogen. The main virulence factors of *B. anthracis* are phagocytosis-inhibiting poly-D-glutamic acid capsule [9] and tripartite exotoxin [10,11]. The anthrax toxin is composed of two enzymatically active components: lethal factor (LF) and edema factor (EF) and one shared receptor binding and translocation component: protective antigen (PA). PA, LF and EF, which are individually nontoxic, combine to form ‘classic’ AB-type binary toxins [12]; lethal toxin (LT = LF + PA) and edema toxin (ET = EF + PA), which are primarily responsible for the anthrax symptoms and lethality. Anthrax toxin-induced cell intoxication involves several stages shown in Figure 1. Full-length PA (PA 83) binds to the cellular CMG2 and TEM8 receptors and, after being cleaved by extracellular furin protease to a 63-kDa form (PA 63), undergoes oligomerization, forming either heptameric [13] or octameric [14] ring-shaped prepropeps. The prepore formation generates three [15] or four [14] LF- and/or EF-binding sites at the interface of two neighboring PA molecules. In addition, the oligomeric prepore formation causes receptor-mediated signaling that triggers endocytosis of the anthrax toxin complexes [16]. Under the acidic endosomal environment, the oligomeric PA 63 prepore undergoes substantial structural changes that allow it to embed into the endosomal membrane, where it forms a cation-selective channel [17]. The protein wall of the oligomeric PA 63 forms a single tunnel, a water-filled pore that connects solutions on both sides of the endosomal membrane. The elongated mushroom-like (of 125 Å diameter with 70 Å long cap and 100 Å long stem) membrane-spanning (PA 63) structures were detected by the negative-stain electron microscopy [18]. PA, then, is believed to act as an effective translocase, which, using the proton gradient across the endosomal membrane (pHendosome < pHcytosol), unfolds and translocates LF and EF into the host cell cytosol. The molecular details of the PA 63 channel acting as the translocase have emerged as result of its intense studies in bilayer membranes [14,19-29]. Briefly, LF transport across the PA channel was directly observed by monitoring the resumption of ion current, originally reduced by channel occlusion by LF, after LF was translocated. Moreover, the translocation of LF was proven to be initiated by entry of its N terminus into the PA 63 channel [20] and driven through by either transmembrane potential [19] or by proton gradient [30] across the membrane. Importantly, the transport of LF through the PA 63 channel, and, as a result, its toxicity were shown to be significantly suppressed by mutating phenylalanine residues at position 427 [21]. The seven (or eight) F427 residues are believed to form a narrow constriction region inside the channel lumen (Φ-clamp) that acts as a translocase active site crucial for the A components transport. Once in the cytosol, LF and EF exert their catalytic activities. LF is a

Successful implementation of these approaches would inevitably be preceded by learning the physics, chemistry and physiology of functioning of biological structures under normal and pathological conditions.

The purpose of this article is to review the main recent strategies of drug design using the discovery of inhibitors against anthrax toxin as a prime example. The intentional dissemination of *Bacillus anthracis* spores in 2001 via the so-called anthrax letters and their fatal consequences led to the 12 years of continuing political and scientific efforts to develop medical countermeasures to protect humans from anthrax and targeted.

Many of the reviewed antitoxins were discovered with the use of innovative rational approaches with special attention paid to the physicochemical properties of lead small-molecule candidates and the physical forces involved in the drug-target interaction.

Polyvalent interactions can be significantly stronger than the corresponding monovalent interactions of the same ligand, thus representing a promising strategy to explore in drug discovery.

Despite recent significant advances in the rational drug design, tailor-made antitoxins are yet to reach the market.

This box summarizes key points contained in the article.

**Article highlights.**

- The intentional dissemination of *Bacillus anthracis* spores in 2001 via the ‘anthrax letters’ led to the 12 years of continuing efforts to develop anthrax toxin inhibitors.
- As our understanding of anthrax tripartite toxin action has advanced, the toxin components (protective antigen, lethal factor and edema factor) became targets of numerous attempts to design effective antitoxins with nearly every step of the toxin pathway explored and targeted.
- Many of the reviewed antitoxins were discovered with the use of innovative rational approaches with special attention paid to the physicochemical properties of lead small-molecule candidates and the physical forces involved in the drug-target interaction.
- Polyvalent interactions can be significantly stronger than the corresponding monovalent interactions of the same ligand, thus representing a promising strategy to explore in drug discovery.
- Despite recent significant advances in the rational drug design, tailor-made antitoxins are yet to reach the market.

---

**2. Mode of action of anthrax toxin**

*B. anthracis*, the causative agent of anthrax, is a large Gram-positive, rod-shaped, aerobic, spore-forming bacterial pathogen. The main virulence factors of *B. anthracis* are phagocytosis-inhibiting poly-D-glutamic acid capsule [9] and tripartite exotoxin [10,11]. The anthrax toxin is composed of two enzymatically active components: lethal factor (LF) and edema factor (EF) and one shared receptor binding and translocation component: protective antigen (PA). PA, LF and EF, which are individually nontoxic, combine to form ‘classic’ AB-type binary toxins [12]; lethal toxin (LT = LF + PA) and edema toxin (ET = EF + PA), which are primarily responsible for the anthrax symptoms and lethality. Anthrax toxin-induced cell intoxication involves several stages shown in Figure 1. Full-length PA (PA₈₃) binds to the cellular CMG2 and TEM8 receptors and, after being cleaved by extracellular furin protease to a 63-kDa form (PA₆₃), undergoes oligomerization, forming either heptameric [13] or octameric [14] ring-shaped prepropeps. The prepore formation generates three [15] or four [14] LF- and/or EF-binding sites at the interface of two neighboring PA molecules. In addition, the oligomeric prepore formation causes receptor-mediated signaling that triggers endocytosis of the anthrax toxin complexes [16]. Under the acidic endosomal environment, the oligomeric PA₆₃ prepore undergoes substantial structural changes that allow it to embed into the endosomal membrane, where it forms a cation-selective channel [17]. The protein wall of the oligomeric PA₆₃ forms a single tunnel, a water-filled pore that connects solutions on both sides of the endosomal membrane. The elongated mushroom-like (of 125 Å diameter with 70 Å long cap and 100 Å long stem) membrane-spanning (PA₆₃) structures were detected by the negative-stain electron microscopy [18]. PA, then, is believed to act as an effective translocase, which, using the proton gradient across the endosomal membrane (pHendosome < pHcytosol), unfolds and translocates LF and EF into the host cell cytosol. The molecular details of the PA₆₃ channel acting as the translocase have emerged as result of its intense studies in bilayer membranes [14,19-29]. Briefly, LF transport across the PA channel was directly observed by monitoring the resumption of ion current, originally reduced by channel occlusion by LF, after LF was translocated. Moreover, the translocation of LF was proven to be initiated by entry of its N terminus into the PA₆₃ channel [20] and driven through by either transmembrane potential [19] or by proton gradient [30] across the membrane. Importantly, the transport of LF through the PA₆₃ channel, and, as a result, its toxicity were shown to be significantly suppressed by mutating phenylalanine residues at position 427 [21]. The seven (or eight) F427 residues are believed to form a narrow constriction region inside the channel lumen (Φ-clamp) that acts as a translocase active site crucial for the A components transport. Once in the cytosol, LF and EF exert their catalytic activities. LF is a

---

**Article highlights.**

- The intentional dissemination of *Bacillus anthracis* spores in 2001 via the ‘anthrax letters’ led to the 12 years of continuing efforts to develop anthrax toxin inhibitors.
- As our understanding of anthrax tripartite toxin action has advanced, the toxin components (protective antigen, lethal factor and edema factor) became targets of numerous attempts to design effective antitoxins with nearly every step of the toxin pathway explored and targeted.
- Many of the reviewed antitoxins were discovered with the use of innovative rational approaches with special attention paid to the physicochemical properties of lead small-molecule candidates and the physical forces involved in the drug-target interaction.
- Polyvalent interactions can be significantly stronger than the corresponding monovalent interactions of the same ligand, thus representing a promising strategy to explore in drug discovery.
- Despite recent significant advances in the rational drug design, tailor-made antitoxins are yet to reach the market.

This box summarizes key points contained in the article.
Zn-metalloprotease which disturbs host cell signal transduction by cleaving mitogen-activated protein kinase kinases (MAPKKs) [31,32] and Nlrp1 [33]. EF is a calmodulin-dependent adenylyl cyclase [34], which aids in dissemination of B. anthracis in the host [35], and its neutralization was shown to significantly prolong survival time in a mouse model of spore infection [36]. The newly identified key tissue targets responsible for the poisonous effects of lethal and edema toxins include two vital systems, the cardiovascular system (LT) and liver (ET) [37]. Notably, targeting cardiomyocytes and vascular smooth muscle cells is required for LT-induced mortality, and action in hepatocytes occurs in ET-induced mortality. At the same time, endothelial cells that were often considered as a key object of LT-induced lethality were not found as primary targets for either LT or ET. The role of endothelial cells was assessed by generating endothelial-cell-specific CMG2 null mice CMG2(EC−/−) and challenging them with 100 µg LT. The authors found that the CMG2(EC−/−) mice had similar sensitivity compared with their CMG2(EC+/+) and CMG2+/+ littermates, whereas whole-body CMG2−/− mice were completely resistant to the toxin. Besides, endothelial-cell-specific CMG2-expressing mice (CMG2EC+/-) survived two doses of 100 µg LT in contrast to their CMG2+/− and CMG2−/− littermates [37]. These recent findings are expected to contribute to our understanding of anthrax infection pathophysiology, which, provided that the documented human anthrax cases [38] are reexamined, would allow for widening the therapeutic window for the investigational anthrax antitoxins to work [37].

### 3. Novel strategies to design inhibitors of anthrax toxin

The events of 2001, when the existing vaccine was not available to the general public and only a limited number of antibiotics were approved by the FDA for the treatment of inhalational anthrax, had stimulated intense search for the new anthrax prophylactic and therapeutic approaches. Considering that humans are only occasionally infected with B. anthracis, vaccination, undoubtedly being one of the most significant medical achievements of the twentieth century, does not seem to provide a realistic solution to the problem. The controversial story of 2002 voluntary withdrawal of the LYMErix™, Lyme disease vaccine, which GlaxoSmithKline found to be economically unpractical to continue marketing, represents a gloomy example of the challenges that vaccine developers might face [39]. Currently, there are several approved and recently discovered [40] antimicrobials with demonstrated ability to kill B. anthracis [41]. However, anthrax infection, especially in its inhalational form, is difficult to treat because flu-like symptoms appear only after B. anthracis have multiplied inside the human or animal host and started to produce the anthrax toxin [42,43]. Even though aggressive antibiotic therapy can
inhibit bacterium growth, the infection can still be lethal because of the accumulation of the toxins [44]. Moreover, engineered strains of *B. anthracis* resistant to the existing antimicrobials have been developed [10,45,46]. Therefore, an effective post-exposure approach to anthrax treatment would most likely include synchronized blockage of bacterial growth by antibiotics and neutralization of anthrax toxin with antitoxins [10,47].

Passive immunization with protective antibodies represents an attractive post-exposure option to combat anthrax infection (reviewed in Ref. [5]). Monoclonal antibodies (mAbs) directed against the major anthrax toxin components, PA, LF and EF, and against the capsule are at the most advanced stage of development. In December 2012, FDA and GlaxoSmithKline have announced the approval ofraxicabumab mAbs for use as a treatment of inhalational anthrax in combination with antimicrobial agents [48]. Raxicabumab efficiency was demonstrated in one study in monkeys and three studies in rabbits and its safety was evaluated in 326 healthy human volunteers. Because of the ethical issues with exposure of healthy human volunteers to aerosolized *B. anthracis* spores, raxicabumab was the first mAb approved under the FDA’s animal efficacy rule, which allows approval of new pharmaceutical entities without testing their efficacy in humans. Several different therapeutically suitable mAbs are currently under development.

On the other hand, using small-molecule therapeutic agents often offers notable advantages when compared with antibodies. Small molecules are especially attractive as antitoxins, since their room temperature shelf-life far exceeds that of the current solution, antisera to toxins. Besides, small-molecule compounds are often orally bioavailable and therefore could be easily administered using ingestible tablets or capsules, which can later reach almost any target in the body, including the intracellular ones. Moreover, with regard to the rational drug design, the small-molecule drug candidate development represents an essentially different technological platform with a variety of classical and innovative approaches available.

Rational drug design involves knowledge of choices. As our understanding of anthrax tripartite toxin action developed, the anthrax toxin components (PA, LF and EF) have become targets of numerous efforts to design the effective antitoxins. Nearly every fundamental step of the toxin’s long intracellular journey have been explored and targeted. The potential antitoxin agents at investigational stages of development include: i) targeting PA-receptor binding; ii) inhibiting extracellular furin; iii) preventing oligomeric PA63 prepore assembly; iv) preventing LF and EF binding; v) preventing endocytosis; vi) targeting oligomeric PA63 prepore-to-pore conversion; vii) inhibiting LF and EF PA-mediated translocation from endosomes; and viii) targeting LF and EF enzymatic activity (Figure 1).

**Figure 1**

**4.1 Antitoxins targeting PA-receptor binding**

PA binding to receptors on the cell surface is the first event in the multistep anthrax toxin’s intracellular transit (Figure 1). Provided effective diagnostics methods are available, any agents inhibiting this step may, in principle, show the benefits of early intervention. PA was found to bind to either one of the two cell-surface receptors, ANTXR1, which is a von Willebrand tumor endothelial marker 8 (TEM8) [50], or ANTXR2, which is capillary morphogenesis protein 2 (CMG2) [51]. Besides, it was shown [52] that integrin β-1, the cell surface von Willebrand A domain protein, is able to mediate anthrax toxin endocytosis. There are at least three different ways to target the receptor-binding step: i) by blocking the receptor-binding domain of PA [53]; ii) by blocking the host cell receptors [54,55]; and iii) by using soluble TEM8 and CMG2 decoy proteins aimed to compete with the natural receptors for PA binding [56]. One of the first successful attempts on disabling anthrax toxin by targeting the cell-surface receptors was reported by Kane’s group in 2006 [55]. Using phage display technology, the authors identified several 12-residue and 7-residue ANTXR1- and ANTXR2-binding peptides. Interestingly, the downstream homology sequence (DHS) was shared by those identified peptides that were able to bind both receptors. Four polyvalent inhibitors were then synthesized by attaching multiple copies of each DHS-containing peptide to liposome scaffolds. The compounds were tested for their ability to neutralize anthrax toxin in RAW264.7 cell assays. The most potent polyvalent inhibitor, liposome functionalized with multiple copies of AWPLSQLDHYSYN peptide, protected the cells from anthrax toxin intoxication with a half-maximal inhibitory concentration IC₅₀ = 40 nM on a per-peptide basis, allowing for > 50,000-fold enhancement of the single peptide activity. The ability of the polyvalent inhibitors to neutralize anthrax toxin *in vivo* was tested in Fisher 344 rats where all the six animals survived when LT (a mixture
of 30 µg of PA and 8 µg of LF) was coinjected intravenously with 400 nmol of the most effective polyvalent inhibitor [55].

More recently, two pilot screen studies were reported where a sensitive high-throughput fluorescence resonance energy transfer (FRET) assay was used in identifying potent small-molecule inhibitors of PA interaction with CMG2 [57] and TEM8 [58]. The assay was based on FRET detected during the interaction of a fluorescently labeled CMG2 or TEM8 with a fluorescently labeled PA and allowed identification of tannic acid and cisplatin, and ebselen and thimerosal as, respectively, CMG2/PA and TEM8/PA interaction inhibitors. Importantly, even though the precise biological functions of the CMG2 and TEM8 receptors in the absence of anthrax toxin have not been fully understood, these proteins were first discovered due to their overexpression on endothelial cells undergoing angiogenesis or blood vessel growth [59]. Targeting angiogenesis is an important strategy for current antitumor therapies, where both methods utilizing small-molecule CMG2 and TEM8 inhibitors and tailored forms of the anthrax toxin have potential for applications.

4.2 Antitoxins inhibiting extracellular furin
Proteolytic activation of PA to the functionally active PA63 by extracellular furin protease triggers PA63 oligomerization to form a receptor-bound heptameric or octameric prepore. Therefore, targeting host cell furin is a coherent therapeutic strategy against anthrax toxin. In particular, one of the potential blockers of Pseudomonas aeruginosa exotoxin A, previously discovered using combinatorial chemistry techniques, small stable furin inhibitor hexa-D-arginine amide (D6R = (D-Arg)₆-NH₂), delayed anthrax toxin-induced toxemia both in vitro and in vivo [60]. Thus, the lead furin inhibitors represent a potential group of compounds for further optimization and development as therapeutic agents against furin-dependent diseases, such as bacterial and viral infections, cancer and Alzheimer’s disease [7]. Further studies have shown that the polyarginine-rich peptides, in general, have an enhanced inhibitory activity against anthrax toxin specifically targeting furin protease. Thus, nona-D-arginine (D9R = (D-Arg)₉-NH₂) demonstrates 30 times increase in activity compared to D6R [61]. Interestingly, the peptides with arginine-rich sequences were also identified as inhibitors of metalloprotease LF [62,63]. In particular, In-2-LF, a peptide hydroxamate, blocked anthrax toxicity in RAW264.7 and J774.A1 cells [62]. The common requirement for arginine-rich sequences between furin and LF inhibitors was addressed in a study where a potential inhibitory cross-reaction of LF and furin inhibitors was investigated [64]. In-2-LF, in addition to inhibiting LF, also inhibited furin, whereas furin inhibitors D6R and D9R inhibited LF. The authors suggested that the combined treatment with both furin and LF inhibitors might represent a more effective approach to the blockage of anthrax toxemia than the use of either inhibitor alone.

More recently, sharply focused and specific antagonists of pathogen entry, nanomolar-range peptide inhibitors of host cell furin and furin-related proprotein convertases, were reported [65]. The authors modified the extended furin cleavage sequence of avian influenza A H5N1 HA. The resulting competitive inhibitors were capable of efficiently obstructing furin proteolysis of anthrax PA₆₃ and avian influenza H5N1 HA in vitro. Importantly, the peptides have also demonstrated efficacy in mice against both anthrax and Pseudomonas exotoxin. The authors later optimized their lead compounds focusing on N- and C-terminal modifications of the original RARRRKKT scaffold inhibitory sequence [66]. The resulting compounds did not interfere with the normal cellular function of furin, meanwhile showing a promising potential as selective anthrax inhibitors. Besides, a series of naturally occurring serine protease inhibitors was screened for the ability to rescue macrophages from LT-induced cytotoxicity. One endogenous protease inhibitor, a member of the inter-α-inhibitor protein (IαIP) complex, was highly protective in this macrophage lethality assay [67] and, when administered with antimicrobial therapy, an hour or up to 24 h after spore challenge with B. anthracis Sterne strain, it protected mice from lethality [68]. IαIP is a large, multi-component, covalently linked glycopeptide-proteoglycan complex that functions as a trypsin-type protease inhibitor. To study the activity of furin inhibitors, an artificial neural network was used for constructing a quantitative structure-activity relationship (SAR) model and exploring different methodologies for classifying and predicting the biological activity of these compounds [69].

4.3 Antitoxins preventing oligomeric PA₆₃ prepore assembly
Considering the need for fast discovery of efficient anthrax antitoxins versus the long and costly FDA-regulated drug approval process, several groups focused their effort on screening for the drugs that are already approved for human use in treatment of different conditions. A table of the related FDA-approved substances that demonstrated a certain level of efficacy against anthrax toxin is provided in a review [8]. Thus cisplatin, one of the most effective chemotherapeutic anticancer agents, protected LT-sensitive macrophages from lysis by inhibiting LF translocation to the cytosol [70]. The authors report that cisplatin acts by modifying PA in a reversible noncovalent manner that does not interfere with its cell binding and processing but prevents the oligomer formation, which is required for LF binding. To confirm this conclusion, the authors tested cisplatin against two other toxins translocated by PA, the anthrax edema toxin and the cytotoxin FP59, a fusion of LF and exotoxin A from P. aeruginosa, and demonstrated that cisplatin inhibited both toxins. Note that the cisplatin’s receptor-binding inhibitory properties were reported [57] as discussed earlier in the present review. Interestingly, the administration of cisplatin pretreated lethal doses of LT resulted in total protection of BALB/c mice and Fisher 344 rats, whereas the administration of cisplatin to mice before or after toxin administration was not protective. The authors explain these data by the cisplatin’s affinity toward thiols, leaving little drug to react with amino
acid side chains of the anthrax toxin proteins, rapid cisplatin clearance from the plasma and a very short half-life in blood. At the same time, identification of the PA residues modified by cisplatin, which leads to inhibition of oligomerization, may provide useful information for both structure/function studies of LF and further drug discovery efforts.

By mimicking key residues of PA63 needed for the heptamer-stabilizing intermolecular interactions, CAVEAT molecular design package was used in designing two molecular scaffolds inhibiting the PA63 oligomerization [71]. The authors reported that three out of seven designed and synthesized compounds showed modest anthrax toxin inhibition in murine J774A.1 macrophage cells. Most recently, using virtual ligand screening of a library of 10,000 members, Wein et al. have identified two lead small-molecule compounds (molecules 5180717 and 5181401 in Figure 2) capable of protecting RAW264.7 and HT1080 cells, independently blocking both PA’s cleavage by furin and subsequent oligomerization [72]. The compounds were originally designed in silico to bind to a pocket on an oligomerization face of PA and then, surprisingly, were shown to reduce the rate of furin cleavage of PA. The authors suggest several interesting structural models to explain this effect. These molecules are believed to be the most effective PA oligimerization-inhibiting compounds reported, and the paper represents the first study demonstrating dual-acting inhibitory effects of the designed blockers.

4.4 Antitoxins obstructing LF and EF binding

One way to disable anthrax toxin action is to block PA63 interaction with LF and EF (Figure 3). The dodecameric peptides that can bind to PA63 and weakly inhibit its interaction with enzymatic components of the anthrax toxins were identified from a phage-display library [73]. However, when multiple copies of these peptides were covalently linked to a polyacrylamide backbone, the resulting polyvalent molecule strongly inhibited LF and EF binding to PA63 and protected cells and animals from the anthrax toxin action. The authors also emphasized that the use of a polymer with a flexible backbone (Figure 3A) [74] would allow the drug designers to avoid the necessity of knowing the spatial relationships among the binding sites on the target, thus extending the applicability of the approach to targets in which these relationships are not yet understood. This approach was further advanced by designing functionalized liposomes of ~50 nm in size, which were allowed to interact with a cysteine-derivatized version of the earlier identified [73] PA63-binding peptides [75]. Remarkably, peptide-functionalized liposomes inhibited the intoxication of RAW264.7 cells by LT at extremely low concentrations (IC50 = 20 nM on a per-peptide basis), whereas the monovalent peptide did not inhibit LT activity at concentra- tions as high as 250 μM. Moreover, the peptide-functionalized liposomes were active in vivo protecting rats from the lethal toxin action. The authors investigated the effect of altering the density of the PA63-binding peptides on the potency of the functionalized liposomes. Herewith, a distinct transition in IC50 values was observed over a narrow range of average distances between the peptides corresponding to their 3.5 – 5 nM bulk concentration, thus demonstrating the importance of pattern matching in recognition of oligomeric PA63 by the polyvalent liposomes. Another approach to match the inhibitor/target pattern guided the synthesis of polyvalent inhibitors of the controlled molecular weight and ligand density and placement along an inert polymeric scaffold (Figure 3B) [76,77]. Such control was achieved by using the reversible addition-fragmentation chain transfer polymerization (RAFT technique) [78].

In rational drug design of polyvalent inhibitors, once a biospecific ligand is identified, the next important step is a search for a suitable and inert scaffold to attach the ligands [79]. To expand the scaffold diversity, the inhibitory peptides were also grafted to the core of β-cyclodextrins (βCD) via polyethylene glycol (PEG) linkers (Figure 3C) [80]. These sevenfold symmetrical molecules were previously used as the scaffolds to design polyvalent PA63 channel blockers (see Section 4.7 below) [81]. The PEG linker length was varied to find an optimal fit of the polyvalent inhibitor to PA63. To achieve an optimal inhibitor/target pattern match, experimental mutagenic studies were accompanied by computational docking experiments searching for a suitable binding site for the inhibitory peptide on the heptameric PA63. The root-mean square distance from the center of cyclodextrin core to the end of the PEG41 linker was estimated as 30 Å, which matched the distance from the center of the PA63 oligomer to the identified peptide-binding residues. The idea of the sevenfold symmetrical functional group placement allowed the authors to reach the IC50 values as low as 10 nM on a per-peptide basis in vitro by incubating RAW264.7 cells with the lethal toxin. The heptameric blocker showed a >100,000-fold increase in the activity compared with the monomeric peptide. The functionalized βCD-based blocker did not show any major decline in activity over a 3-day period and was also effective in vivo protecting rats from intoxication by LT.

4.5 Antitoxins preventing endocytosis

AB-type toxins rely on target cell receptors to reach their desired intracellular targets. At the same time, PA binding to the extracellular domain of the anthrax toxin CMG2 and TEM8 receptors and its subsequent oligomerization was found to activate specific signaling events. Thus, anthrax toxin was shown to trigger tyrosine phosphorylation of its own receptors, which is required for toxin uptake because endocytosis of the mutant receptor lacking the cytoplasmic tyrosine residues was significantly slowed down [82]. Herewith, receptor phosphorylation was found to depend on src-like kinases, which were activated because of toxin binding. The src-dependent phosphorylation of the receptor was critical for its later ubiquitination required for clathrin-mediated endocytosis [83]. More specifically, to test the importance of tyrosine phosphorylation events in toxin uptake, the authors analyzed the effect of genistein, which is the general tyrosine
phosphorylation inhibitor. Since the cleavage of the LF-target MAPKKs MEK1 was not observed in genistein-treated cells, LF was not delivered to the cytoplasm. By blocking the activation of src-kinases, genistein inhibited endocytosis of the PA oligomeric complex. Even though genistein was used in investigating the mechanism of anthrax toxin endocytosis, the study suggests new possible targets for the rational design of anthrax antitoxins [82].

Most recently, a high-throughput screening of 30,000 small-molecule compounds was used in identifying 4-bromobenzaldehyde N-(2,6-dimethylphenyl)semicarbazone (EGA)…

Figure 2. Structures of small-molecule anthrax toxin inhibitors and their modes of binding to PA are shown. (A) The compounds investigated in Ref. [72]; (B) PA crystal structure 1T6B (red ribbon) superimposed on the crystal structure 3TEW (gray ribbon) with the ordered furin loop in 3TEW highlighted in blue are shown. The furin-type protease cleaves after the sequence 164RRKR, which is shown in stick representation with carbon atoms colored blue. The predicted binding poses for inhibitors 5180717 and 5181401 are displayed in stick representation with carbon atoms colored yellow and gray, respectively. The binding pocket surface for 1T6B used for virtual screening is displayed (white = neutral surface, green = hydrophobic surface, red = hydrogen bonding acceptor potential, blue = hydrogen bond donor potential). (C, D) Predicted interactions of 5180717 (yellow stick) and 5181401 (gray stick), respectively, with PA are shown. Both ligands make common hydrogen bonds with Q158, Q483, and K157.

Reprinted with permission from [72]. © 2012. American Chemical Society.
as the most active inhibitor of endosomal trafficking [85]. The authors suggest obstruction of trafficking between early and late endosomes as the likely mechanism of the inhibition. Besides, EGA was shown to block the entry of pH-dependent bacterial toxins, such as *P. aeruginosa* ExoA and diphtheria toxin DT, which share similar cellular entry requirements with LT. EGA was also reported to inhibit the pH-dependent viral entry – the result showing EGA’s potential to become a powerful tool for the study of membrane trafficking.

### 4.6 Antitoxins targeting oligomeric PA63 prepore-to-pore conversion

Prepore to pore transformation is an important step in anthrax toxin intracellular transport, which requires essential structural reorganization in the PA oligomer (recently reviewed in Ref. [86]). Several small-molecule blockers impairing the PA heptamer prepore-to-pore conversion in cells expressing the CMG2 receptor were identified with a quantitative high-throughput screening [87]. The method was based on a cell pathway assay that monitors receptor-mediated endocytosis of a modified, nontoxic anthrax toxin LF-β-lactamase-PA complex [88]. Among the most effective compounds identified were the i) novel chromeno[4,3-c]pyrazol-4(1H)-one (NCGC00084148-01); ii) lignan diphyllin; and iii) teniacide niclosamide. The inhibitors were shown to protect RAW264.7 macrophages from anthrax lethal toxin and CHO cells from the LF-*Pseudomonas* exotoxin fusion protein and diphtheria toxin. Interestingly, none of the compounds was shown to block cellular binding, proteolytic processing,
heptamerization of PA or PA-mediated LF-binding. Instead, the identified inhibitors influenced the heptamer prepore-to-pore conversion by inhibiting toxin internalization and/or trafficking to endosomes of increased acidity. An isolated anti-PA mAb, cAb29, was shown to effectively neutralize anthrax toxin [89]. By systematic evaluation of the steps that take place during the PA-based intoxication, the authors found that cAb29 did not interfere with the initial steps of intoxication (receptor binding, proteolytic cleavage, oligomerization, prepore formation and LF binding) [90]. However, the cAb29 binding to the prepore prevented its pH-activated opening to the transmembrane pore, thus blocking the LF/EF translocation into the cytosol.

### 4.7 Antitoxins blocking LF and EF PA-mediated translocation

After endocytosis, PA mediates the process of LF/EF translocation across the endosomal membrane inside the cell. A widely accepted traditional model of LF/EF transport into the cytosol of the host cell states that under acidic endosome conditions PA forms a cation-selective channel that unfolds and translocates LF and EF into the host cell cytosol. This model is supported by a number of careful experiments with conditions PA forms a cation-selective channel that unfolds and translocates LF and EF into the host cell cytosol. This model is supported by a number of careful experiments with single PA channels reconstituted in planar lipid membranes recently reviewed in Refs [28,91,92]. The reconstitution experiments demonstrate convincingly that PA channels are able to serve as transmembrane conduits of the factors, with transport parameters depending on membrane voltage, pH gradient and other conditions. An alternative mechanism, in which the anthrax toxin catalyzes the rupture of the endosomal membrane, thereby releasing the toxins into the cytoplasm, was also recently suggested [93]. Regardless, it is important to note here that a variety of available and rationally design compounds aimed to specifically disrupt the steps of intoxication (receptor binding, proteolytic cleavage, oligomerization, prepore formation and LF binding) [90]. It was found that the PA63 channel is permeable for and can be blocked by tetraalkylammonium ions [103-105]. The inhibition of the channel conductance by small molecules carrying one or two positive charges was also reported [21,106,107].

Initially, the ability of the cationic compounds to block PA63 was explained by their Coulombic interactions with the binding sites formed by the negatively charged amino acid residues in the cis entry region of the channel. An alternative explanation involved interaction of cationic compounds with the Φ-clamp, which was also shown to be crucial for the PA63 translocase activity [21]. Across the studied library of molecules, the Φ-clamp preferred aromatic moieties by 0.7 kcal/mol/aromatic ring. Several compounds with multiple aromatic rings were the ones that showed the promising nanomolar range of binding affinity toward the channel. The Φ-clamp mutations were shown to significantly affect binding affinity of hydrophobic cations. The blocker/PA63-binding reaction was suggested to include cation–π interactions between aromatic residues and cations through their delocalized negative π-electron cloud.

A considerable progress in inactivating anthrax toxin by the high-affinity blockage of the PA63 pore with cationic compounds was achieved using a rational design of sevenfold symmetrical positively charged derivatives of βCD (7pβCD) schematically illustrated in Figure 4 (recently reviewed in Ref. [108]). The PA63 prepore internal diameter was estimated to be between 20 and 35 Å [13] with the PA63 pore’s constriction region not exceeding 12 Å [103-105]. This finding directed the choice of the ~15-Å sevenfold symmetrical βCD molecules carrying seven positive charges covalently linked to the cyclo-DEXDRAX’s core by hydrocarbon linkers of different nature and length. One of the first synthesized compounds, the so-called AmPrβCD is shown in Figure 4A (top). To optimize this molecule, the effect of the positively charged pendant groups and the length and nature of alkyl spacers on the activity of 7pβCDs was investigated [109-111]. First, a group of hepta-6-thia-oaminoalkyl derivatives with alkyl spacers of increasing lengths was tested for their ability to both inhibit the lethal toxin cytotoxicity and to block ion current through the PA63 channels in planar lipid bilayers [109]. The two methods showed that there is an optimal length of the alkyl spacers (3 – 8 CH₂-linkers) between the amino group and the cycloextrin core. Short spacers (1 and 2 CH₂-linkers) were less effective in inhibition of the channels, apparently limiting compound’s polyvalent properties. The molecules with longer spacers (9 and 10 CH₂-linkers) exhibited higher toxicity to the RAW cells and caused bilayer lipid membrane rupture. Second, in order
to check the influence of the nature of the positively charged
groups on compound’s efficiency, a group of hepta-6-guanidine βCD derivatives, in which positive charges were
distributed between the nitrogens of the guanidine moiety,
was tested. The activity of these compounds was decreased
only slightly compared to their aminoalkyl analogs. More
importantly, hepta-6-arylamine βCD derivatives, which in
addition to the pendant amino groups contained one phenyl
group per each thio-hydrocarbon linker, possessed noticeably
greater binding affinity in vitro, in cell assays, and in vivo.
These blockage and inhibition parameters are among the best published for the small-
molecule anthrax toxin inhibitors. It was reported that
AMBnTβCD is several times more efficient than the most
different non-peptide blockers of ion-selective channels of excit-
able membranes, including the classical sodium channel
blocker tetrodotoxin, whose dissociation constant is
close to 1 nM. Most importantly, AMBnTβCD completely
protected Fisher F344 rats from intoxication with lethal toxin
and, in combination with antibiotic ciprofloxacin, significantly
increased the survival of mice in an infection model of
anthrax. In addition to inhibition of anthrax toxin, posi-
tively charged βCD derivatives were also effective against clos-
tridial binary toxins.

Figure 4. Schematic representation of blocking anthrax on a single-channel level. A. Two sevenfold symmetrical synthetic molecules, AmPrβCD (top panel) and AMBnTβCD (bottom panel) were used as blockers of PA63 channels. B. A heptameric mushroom-like channel of PA63 believed to be a translocation pathway for LF and EF inside the cell under attack (top) is shown. The idea was to design complementary heptameric low-molecular weight compounds – cationic cyclodextrins (bottom) that enter the channel and block it as molecular plugs. The cartoon is a simplified illustration of the LF and EF penetration into the mammalian cell. In reality, the process is much more complex.

Reprinted with permission from [116,162]. With permission from Elsevier.
EF: Edema factor; LF: Lethal factor; PA: Protective antigen.
To examine the nature of the physical forces involved in the pore/blocker binding reaction, voltage and salt dependences of the rate constants of binding of the two structurally different βCDs (AmPr βCD and AMBnT βCD) to the PA63 channels were recently investigated [116]. The authors found that the blocking efficiency directly correlated with the presence of aromatic groups carried by the cationic molecules and that F427A was the prime site for the pore-blocker interaction. By estimating the relative contributions of the applied transmembrane field, long-range Coulomb, and salt concentration-independent, short-range forces, it was reported that the latter represent the leading interaction, which accounts for the high efficiency of the blockage. The particular origin of these forces was unclear. At this moment, guided by the structural features of the efficient cyclodextrin-based blockers, one can only speculate that in addition to hydrophobic interactions many others such as aromatic-aromatic π-π and cation-π interactions, hydrogen bonding, van der Waals interactions, and the like might be involved.

It was also reported that even though the sevenfold symmetry of the blocker molecules complementing the heptameric structure of PA63 was important, it was not an absolute requirement for the effective blockage. Both sixfold symmetrical γCD carrying six positive charges and eightfold symmetrical γCD carrying eight positive charges were able to block the PA63 channel in planar lipid membranes [111]. The activity of the 8+γCDs tested with cell assays was equal or even higher compared with their 7+βCD analogs, whereas binding of 6+αCD was not strong enough to make these compounds protective against anthrax toxin. It was suggested that the inhibitory activity of the eightfold symmetrical γCDs could be related to the reported observation of the PA63 octameric pores [14]. However, both positively charged βCDs and γCDs were able to block any single PA63 channel incorporated into planar lipid bilayers. This indicates that it is the polyligand nature of these cyclical compounds rather than the exact pore/blocker symmetry match that determines their enhanced efficiency. These findings demonstrate the value of the 7+βCD and other polyvalent inhibitors for designing drugs against anthrax toxins, especially when an appropriate lead optimization and pharmacokinetic studies are conducted.

Note that in a number of studies, cells were shown to be protected from lethal and edema toxin action by weak bases, such as ammonium chloride or antimarial drug chloroquine as well as by proton pump inhibitors, such as bafilomycin A [117-120]. It is interesting that chloroquine, which is known to reversibly block PA63 [106], is also discussed in the literature in regard to its ability to block endosomal acidification by raising endosomal pH [121]. Moreover, a group of the FDA-approved small-molecule compounds that presumably block LF or EF transport by changing endosomal pH was reported [87,122]. It would be interesting to evaluate what degree the other pore-blocking cationic compounds are able to influence the endosomal pH which is known to be critical for both PA63 pore formation and LF/EF translocation. At the same time, we cannot exclude a possibility that some of the cationic compounds may interact with the PA63 prepore outside the cell. Some indications of such interactions were reported for the βCD-based inhibitors [123].

### 4.8.1 Antitoxins targeting LF enzymatic activity

While the antitoxins discussed so far were mostly targeting PA, the molecules described in this and the following sections are specific for the causative agents that disrupt cell functioning, namely anthrax toxin’s catalytic moieties. PA as a target has certain shortcomings that shift the focus of the current antitoxin research toward LF. In contrast to less stable PA, LF remains active in cells and in animal tissues for days, as manifested by continued cleavage of MAPKs proteins by the toxin [124]. Moreover, PA was recently shown to translocate LF not only into the cytosol but also into the lumen of endosomal intraluminal vesicles that can later fuse and release LF into the cytosol. As a result, LF can survive in the vesicles for days being fully protected from proteolytic degradation [125]. Therefore, efficacy of the post-exposure treatment with PA-targeting drugs can be time-dependent, being more effective at the early stages of infection. Since the discovery of one of the first LF inhibitors in 2002 [62], numerous research efforts to search for the ‘ideal’ LF inhibitor were undertaken. Because of the great number of these studies, which are reviewed elsewhere [7,127-129], the examples below are not exhaustive and rather serve the specific scope of the current review. Although LF and EF inhibitors can act at any appropriate stage of the toxin’s pathway, for instance by preventing LF/EF interaction with PA, most of the designed compounds perform intracellularly by inhibiting the metalloprotease activity of LF or the adenylase cyclase activity of EF.

For that purpose, the rational design efforts to target the catalytic moieties of the anthrax toxin mostly focused on small-molecule (non-peptide) compounds that are able to pass the transmembrane barrier and find their intracellular target. Peptide-based compounds are less likely to reach the required inhibitory concentration in the cytosol. Thus, three small organic LF inhibitors with 50% values in the 0.5 – 5 μM range were identified using LF X-ray crystal structure and structure-based molecular diversity screening combined with 3D database searching and molecular modeling [130]. The hydroxamate LF inhibitor that can co-crystallize with LF at the LF-active state was identified [131]. The molecular interaction between the inhibitor and LF led to inhibition of LF catalytic activity in a cell-based assay and complete protection in a lethal mouse toxemia model. Moreover, a 50% improvement in survival was reached in mice challenged with B. anthracis Sterne vegetative cells and in rabbits challenged with B. anthracis Ames spores. When the compound was used in combination with a specific antimicrobial agent ciprofloxacin, 100% protection against B. anthracis spore challenge
was demonstrated. At the same time, ciprofloxacin alone provided only 50% protection.

Several chemically distinct classes of small and peptide-based polycationic molecules have been identified as LF metalloprotease inhibitors. For example, a small library of ~500 compounds of several chemical classes has been screened to identify molecules that would specifically bind to the anionic sites on LF and block the substrate cleavage [132]. Using a fluorescence-based assay, a number of positively charged inhibitory molecules including polyamines, aminoglycosides and cationic peptides were identified and characterized. In these studies, spermine was shown to inhibit LF with the $K_i$ value of 0.9 μM. Besides, a detailed kinetic investigation of aminoglycoside neomycin B and neamine binding was reported, which showed that these molecules act as mixed-type noncompetitive inhibitors of LF [133]. The paper offers interesting discussion aimed to explain the discrepancy between the data on molecular details governing the inhibition of the LF protease by aminoglycosides reported in literature, namely, strictly competitive [134] versus noncompetitive [133] binding. Understanding the difference between the two mechanisms can indeed have important implications in the rational design of LF inhibitors. It is questionable if these cationic compounds can reach a sufficient endosomal concentration to influence LF transport by changing the endosomal pH, as it was claimed for chloroquine, or act by blocking the PA channel, similar to what was reported for the positively charged cyclodextrins and other small-molecule cationic compounds.

LF was also neutralized in vivo by a group of α-defensins produced by the human neutrophils [135]. The mechanism of protection involved inhibition of cleavage and restoration of the signaling function of MAPKK. The cyclic octadecapeptides, encoded θ-defensins by the modified α-defensin genes of nonhuman primates were shown to inhibit the antrax infection in two ways. In addition to being active against B. anthracis cells, θ-defensins inhibited LT by binding to it with high affinity in the experiments with RAW264.7 cells [136]. Another approach to inhibit LT was developed in a study where the importance of the N-end rule for LT-mediated caspase-1 activation and cell death was established [137]. The authors also showed that bestatin methyl ester, an aminopeptidase inhibitor, protected against LT both in vitro and in vivo and that different inhibitors of the protein degradation pathway act synergistically in protecting against LT.

A new pharmacophore map assembly designed to rapidly identify and prioritize promising LF inhibitor scaffolds from virtual compound libraries was reported [138]. The authors utilized structural information from five available LF enzyme-inhibitor complexes deposited into the Protein Data Bank and considered all three key subsites of the LF catalytic binding region. The usefulness of the model was confirmed experimentally. It is known that among hundreds of the small molecule LF inhibitors designed only a limited number of compounds were active in cell protection assays. The authors performed a validation study on 546 compounds previously tested and successfully identified 72% of the existing nanomolar-level inhibitors, while rejecting 100% of the weakly active (>100 μM) compounds.

A group of small-molecule LF blockers with subnanomolar inhibitory constants was described in a series of four consecutive publications. Part 1 and 2 report the identification of several core structures capable of inhibiting LF with $K_i$ values of about 10 nM and in vivo efficacy in rat LT model of anthrax [139,140]. The identified lead structures were further optimized to provide subnanomolar $K_i$ values (part 3 Figure 5A [141]. The efficacy evaluation was performed by comparing the potential for toxicity, physicochemical properties, in vitro ADME profiles and relative efficacy in the rat LT model. Based on these results, the authors then reported that these blockers protected against lethality caused by anthrax infection in mice when combined with subprotective doses of either antibiotics or neutralizing mAbs targeting edema toxin [124]. Importantly, the identified inhibitors also provided protection against lethal infection when administered as a monotherapy. The two doses (10 mg/kg) administered at 2 and 8 h after spore infection were sufficient to provide a significant survival benefit in infected mice. Besides, administration of the blockers early in infection inhibited vegetative bacteria dissemination to the organs in the first 32 h following infection. Importantly, the authors demonstrated the direct correlation between ability to target LF after it has entered cells and survival outcome, emphasizing the importance of LF as the target.

4.8.2 Antitoxins targeting EF enzymatic activity

For anthrax infection models, the LF:EF ratio is reported to be close to 5:1 [142-144], and EF, a calmodulin (CaM)-activated adenylly cyclase toxin, is believed to reach lethal doses in the very late stages of infection [37]. This circumstance shifted the focus of the search for antitoxins toward the more universal PA and more active LF; however, a number of EF blockers were also identified and reported. Advancements in the development of EF inhibitors have been discussed in a series of review articles [145,146], including the most recent one [147]. Thus, EF was neutralized by a number of mAbs [53,148-150]. In particular, chimpanzee/human mAb, EF13D neutralized EF in vitro in the subnanomolar range and its effectiveness was shown in mice [148]. EF13D was shown to bind to a conformational epitope on EF and to inhibit CaM-mediated activation of EF by outcompeting CaM for binding to EF and replacing the prebound CaM in the EF-CaM complex. The critical amino acid residues responsible for mediating EF13D- EF interactions were then identified providing an insight into the molecular basis of the EF13D activity [150].

Several small-molecule inhibitors of EF were discovered [151-156]. The investigational EF neutralizing drugs target the catalytic site of EF, the EF-CaM interaction site, and the allosteric sites. While the compounds targeting the catalytic site were among the most potent reported, adjusting their
selectivity toward EF was problematic [147]. Many of the discovered compounds were also interacting with mammalian membranous adenylyl cyclases, mACs. Using the structure of the catalytic site of EF, 24 commercially available small molecular weight chemicals were screened to identify inhibitors of adenylyl cyclase activity of EF [151]. A quinazoline compound, ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate was found to bind competitively to the adenine portion of the ATP-binding site on EF with $K_i \sim 20 \mu$M. Adefovir diphosphate (PMEApp), a clinically approved drug for chronic hepatitis B virus infection, was found to inhibit EF with a much higher affinity in vitro, $K_i \sim 27 \text{nM}$ [156]. PMEApp demonstrated the affinity for the EF catalytic site that is four orders of magnitude higher than the affinity of ATP for EF. To determine molecular basis for this difference, the authors identified the molecular structure of the EF-CaM in complex with PMEApp, which revealed that the catalytic site of EF forms better van der Waals contacts and more hydrogen bonds with PMEApp than with ATP.

The most potent EF inhibitor, 3¢-(N-methyl)anthraniloyl-2¢-deoxyadenosine-5¢-triphosphate ($K_i = 10 \text{nM}$) [157,158], was one of the investigated (M)ANT-nucleotides, which carries a fluorescent (N-methyl)anthraniloyl group to bind different nucleotide-binding proteins (Figure 5B, left) [147]. However, an additional problem that the developers of the ET inhibitors has faced was related to the high hydrophilicity and, therefore, low membrane permeability of the inhibitors determined by the nucleotide-based structure of the compounds. Based on this and similar crystal structures of EF alone or complexed with substrates and small molecule inhibitors, a structure-based method to search for potential non-nucleotide EF inhibitors was described [152]. A 3D-pharmacophore that fits the active site of EF was constructed from fragments (so-called fragment-based 3D-pharmacophore and in silico screening) to identify small-molecule EF inhibitors. For this purpose, a library of small-molecule fragments was docked into the EF active site and ranked according to their docking scores. As a result, 19 best-scored compounds were tested in a cell assay for their ability to reduce cAMP secretion induced by EF, and it was found that four structurally different compounds inhibited EF in the low micromolar range. Recently, the same group published a study aiming to redesign one of the several initial ‘hits’, (3-[9-oxo-9H-fluorene-1-carbonyl]-amino)-benzoic acid) or
DC-5 (also referred as compound 1 and FIV-50), to search for derivatives that would have similar or better activity, improved aqueous solubility and reduced toxicity [159]. Molecular docking was used in predicting the potency and solubility of the new derivatives. The positions important for compound’s activity were identified using the SAR analysis of the bioassay results. As a result, pharmacological properties of the lead DC-5 compounds were significantly improved by modifying the benzoic acid ring and switching from a hydrogen-bond donor group (-COOH) to a hydrogen-bond acceptor group (-C(=NH)NH₂) (Figure 5B, right). Besides, a number of thiophen ureidoacid inhibitors, with the most efficient one inhibiting the EF activity at \( K_i \approx 10 \, \mu\text{M} \), were identified using rational structure-based design that strategically targeted allosteric pockets [153]. The binding of CaM to EF induced the closed-to-open state transition that reorganized the EF catalytic site into the active configuration that can convert ATP into CAMP. The transitions of the EF allosteric site between known active and inactive conformations were used for virtual screening to search for the candidate EF inhibitors. This approach has allowed identifying a targetable pocket that underwent major reorganization during the EF activation transition. We refer the readers for the details of both DC-5- and thiophen ureidoacid-based inhibitor design to two recent reviews authored by the groups that performed the studies [145,146].

5. Expert opinion

The events of 11 September 2001 and the following intentional dissemination of the ‘anthrax letters’ led to the 12 years of continuing research efforts to develop medical countermeasures to protect humans from anthrax bioterrorism [4]. Significant research attention was focused on gaining understanding of \( B. \) anthracis through the details of anthrax pathogenesis and host responses, as well as on developing vaccines, antitoxins and antimicrobial agents. Mass vaccination, being among one of the most significant achievements of the twentieth century, seems to be economically impractical with certain types of infectious agents. Antibiotics for a long time have been a favored treatment for bacterial infections. However, antibiotic therapy is most effective only at the early stages of anthrax infection. The infection can still be lethal because of the accumulation of the tripartite anthrax toxin even when bacteria have been cleared from the host. Besides, strains of \( B. \) anthracis that are resistant to the effect of antimicrobial agents have been engineered. What makes the situation even worse, at the early stages of inhalational anthrax infection the flu-like symptoms of the disease could be difficult to differentiate from other illnesses. After all, few doctors in the USA and other Western countries have ever seen a single anthrax patient. These and similar considerations urged the government and the scientific community to search for new effective anthrax antitoxin agents. Numerous research publications focusing on targeting every possible stage of the anthrax toxin pathway were soon to follow. However, 12 years later, the options to combat anthrax toxin lethality are still limited. With the only anthrax toxin-inhibiting therapy (PA-targeting with a mAb, raxibacumab) approved for treatment of inhalational anthrax in 2012, in our view, the situation is still insecure. First, the FDA’s animal rule for drug approval, which clears compounds without validated efficacy studies on humans, creates high level of uncertainty [160]. This is especially true when a well-characterized animal model for predicting the response in humans does not exist. Second, Moayeri et al. reported that unlike PA, which is known to be unstable, LF remains active in cells and in animal tissues for days, as manifested by continued cleavage of MAPKKs proteins by the toxin during this time [124]. For instance, antibody therapies against PA, LF or EF administered later than 24 h after infection were shown to rarely provide protection in a mice model. Therefore, the efficacy of the post-exposure treatment of the individuals with anti-PA therapeutics can be time-dependent, requiring coordinated use of membrane-permeable small-molecule inhibitors that would block the LF and EF enzymatic activity intracellularly.

One of the interesting approaches that we would like to highlight explores the idea of attaching multiple functional groups onto an inert scaffold and creating the so-called multivalent interaction between the polyvalent therapeutic agent and the target. These cooperative interactions can be significantly stronger than the corresponding monovalent interactions of the same ligands [79]. The examples include potent biospecific peptide-based or small-molecule ligands (or functional groups) attached to a variety of scaffolds formed by the liposomes [75], polymers [76], or cyclodextrins [80,81]. The strength of specific binding of some of these molecules has been manipulated with a series of rational chemical and structural modifications. In a number of these studies, the polyvalent blockers were designed with a specific universal target in mind: the ion-conductive transmembrane pores formed by channel-forming components of the binary bacterial toxins [115]. Focus on this universal target might lead to development of new pharmacological strategies that, in line with the ‘next-generation research’ agenda put forward by the National Institute of Allergy and Infection Diseases, NIH, are based on the development of broad-spectrum drugs versus the traditional ‘one bug-one drug’ approach.

There are still serious gaps between the current drug discovery approaches that academic laboratories and small biotech companies can offer and the trial and error methods that pharmaceutical giants traditionally use. Whereas the former focus on the innovative approaches and greater-than-ever understanding of the disease, the latter concentrate on the drug-delivery and side-effect aspects, such as compound’s solubility, permeability, removal rate and toxicity. For instance, we found only several mentioning of the classic Lipinski’s rule of five [161], which allows evaluation of drug likeness of a small-molecule compound, in the academic research devoted to the development of anthrax toxin inhibitors. Without
Designing inhibitors of anthrax toxin

by paying attention to these impediments, rational drug discovery programs will find themselves in a disadvantage while competing with big pharma’s dollars. The good news is that the situation may be expected to improve. The research on the rational design of PA channel-blocking antitoxins offers several interesting examples. For instance, polyvalent cationic BCD-based inhibitors may possess higher toxicity than their uncharged analogous. However, it was demonstrated that most of the attractive interactions responsible for the high binding strength of the compounds to their PA target are due to the short-range forces other than Coulombic [116]. This finding opens new prospects in optimizing these lead compounds. Then again, the recently designed cationic aromatic-rich PA-blocking chloroquine-related azolopyridinium salts [107] may offer an advantage due to their low toxicity and ability to permeate through lipid bilayer part of biological membranes in mammalian organisms.

To conclude, we believe that a successful anthrax toxin therapy of the future will include combination polytherapies, where the action of the effective antimicrobials will be enhanced by the antitoxin agents specifically designed to target the A (LF, EF) and B (PA) components of the toxin, similar to what is used in the current tuberculosis, leprosy, cancer, malaria and HIV/AIDS treatments. The polytherapies may also involve the innovative approaches where a possible dual role of the designed antitoxins would be exploited. For instance, the ability of liposomes and cyclodextrin-based nanoparticles to deliver low-soluble drugs was widely studied and utilized. The polyvalent liposome and cyclodextrin anti-toxins can, therefore, be investigated and optimized to act as the double-functioning agents designed to simultaneously disable toxin components and to deliver other small-molecule compounds, either covalently attached or dissolved in their inner cavities, to the desired target. We hope that these strategies will be among the main subjects of future research.

Declaration of interest

EM Nestorovich has received startup funds from the Catholic University of America. SM Bezrukov has received funding from the Intramural Research Program of the NICHD, National Institutes of Health.

Bibliography

Papers of special note have been highlighted as either of interest (●) or of considerable interest (★★) to readers.

20. Zhang S, Finkelstein A, Collier RJ. Evidence that translocation of anthrax...
toxin’s lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc Natl Acad Sci USA 2004;101:16756-61


• The article was the first to describe the phenylalanine clamp importance in PA-facilitated transport of LF and EF and to highlight the role of hydrophobic interactions in designing small-molecule pore inhibitors.


34. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982;79:3162-6


• The most recent study identifying the key tissue targets responsible for the poisonous effects of lethal and edema toxins.


40. Martchenko M, Jeong SY, Cohen SN. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci USA 2003;100:5170-4

41. Martchenko M, Jeong SY, Cohen SN. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci USA 2003;100:5170-4


48. Fox JL. Anthrax drug first antibacterial mAb to win approval. Nat Biotechnol 2013;31:8

• The article highlights a recent approval of rabaxacumab mAbs for use in inhalational anthrax treatment.


56. Cai C, Che J, Xu L, et al. Tumor growth inhibition of tumor-specific antisense to human endodermal marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as...
Designing inhibitors of anthrax toxin


59. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) 2011;16:1574-88


An article promoting the idea of polyvalency as a perspective drug design strategy.


82. The first study to demonstrate PA pore blocking by cationic BCD.

83. Abram L, Kunz B, van der Goot FG. Anthrax toxin triggers the activation of src-like kinases to mediate its own uptake. Proc Natl Acad Sci USA 2010;107:1420-4


86. A comprehensive review of the essential structural reorganization in the PA oligomer during pore formation.

Expert Opin. Drug Discov. (2014) 9(3)

E. M. Nestorovich & S. M. Bezrukov


• An early work investigating dominant negative PA mutants as antitoxins.


101. Montal M, Mueller P. Formation of bimolecular membranes from lipid monolayers and a study of their electrical properties. Proc Natl Acad Sci USA 1972;69:3561-6


• A recent review focusing on the rational drug design of pore-blocking antitoxins.


117. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 1986;261:7123-6

118. Gordon VM, Leppla SH, Hewlett EL. Inhibitors of receptor-mediated endocytosis block the entry of bacillus anthracis adenylate cyclase toxin but not that of bordetella pertussis adenylate
119. Finkelstein A. The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin. Toxicology 1994;87:29-41


124. The article highlights the importance of small molecule LF inhibitors acting intracellularly at the later stages of infection.


129. Tonello F, Montecucco C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.


133. The study offering a biophysical insight into the molecular details of LF inhibition by aminoglycosides reported in literature, differentiating between strictly competitive and noncompetitive binding.


148. The most recent review on the EF inhibitors.


151. Makiya M, Dolan M, Aguito L, et al. Structural basis of anthrax edema factor
neutralization by a neutralizing antibody. Biochem Biophys Res Commun 2012;417:324-9


• An informative ‘News’ article discussing nuances of the FDA’s ‘animal rule’.


• A fundamental and influential medicinal chemistry publication where the Lipinski’s ‘Rule of 5’ was first described.


Affiliation
Ekaterina M Nestorovich† & Sergey M Bezrukov.‡
†Authors for correspondence
‡The Catholic University of America, Department of Biology, Washington, DC, USA Tel: +1 202 319 6723;
E-mail: NESTOROVICH@cua.edu
‡Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Program in Physical Biology, Bethesda, MD 20892, USA Tel: +1 301 402 4701;
E-mail: BEZRUKOS@mail.nih.gov